METASTATIC CUTANEOUS MELANOMA
Clinical trials for METASTATIC CUTANEOUS MELANOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CUTANEOUS MELANOMA trials appear
Sign up with your email to follow new studies for METASTATIC CUTANEOUS MELANOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on Hard-to-Treat melanoma
Disease control Recruiting nowThis study tests a new treatment made from donor immune cells (CAR-NK cells) that are designed to attack two targets on melanoma cells. It is for adults with advanced melanoma that has spread or cannot be removed and has not responded to standard therapies. The goal is to find a …
Matched conditions: METASTATIC CUTANEOUS MELANOMA
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Custom-Made vaccine trains immune system to fight advanced cancers
Disease control Recruiting nowThis early-phase trial is testing a personalized vaccine made from each patient's unique tumor mutations. The vaccine is given along with an immune booster (poly ICLC) to help the body's T cells attack the cancer. The study includes up to 25 adults with advanced melanoma, breast …
Matched conditions: METASTATIC CUTANEOUS MELANOMA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called NUC-7738, given alone or with another drug (pembrolizumab), in people with advanced solid tumors or lymphoma that haven't responded to other treatments. The goal is to find the safest dose and see if it can shrink tumors or slow cancer growth. A…
Matched conditions: METASTATIC CUTANEOUS MELANOMA
Phase: PHASE1, PHASE2 • Sponsor: NuCana plc • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Morning vs. evening: can timing boost melanoma treatment?
Disease control Recruiting nowThis study tests whether giving standard immunotherapy drugs (ipilimumab and nivolumab) in the morning works better than giving them later in the day for people with advanced melanoma that has spread or cannot be removed. About 99 adults with stage IV melanoma will be randomly as…
Matched conditions: METASTATIC CUTANEOUS MELANOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Promising new combo tackles melanoma brain metastases in phase 2 trial
Disease control Recruiting nowThis phase 2 trial compares two treatment combinations for people with BRAF-V600 mutant melanoma that has spread to the brain. One group gets a targeted therapy (encorafenib and binimetinib) plus an immunotherapy (nivolumab), while the other gets two immunotherapies (ipilimumab a…
Matched conditions: METASTATIC CUTANEOUS MELANOMA
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 26, 2026 15:43 UTC
-
Cancer patients may soon get immunotherapy at home instead of the clinic
Symptom relief Recruiting nowThis study compares giving the cancer drug nivolumab (Opdivo) as a shot at home versus in a clinic for people with various advanced cancers. The goal is to see if home treatment improves patients' overall care experience and quality of life. About 50 adults will receive the drug …
Matched conditions: METASTATIC CUTANEOUS MELANOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Blood test aims to spot hidden cancer cells in 9 tumor types
Knowledge-focused Recruiting nowThis study is looking for certain cells in the blood of people with 9 types of advanced cancers that have spread. Researchers will take one blood sample from each of 450 participants before they start a new treatment. They will use two different lab methods to see if they can fin…
Matched conditions: METASTATIC CUTANEOUS MELANOMA
Phase: NA • Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC